<DOC>
	<DOCNO>NCT02380313</DOCNO>
	<brief_summary>This study conduct characterize safety recommend phase 2 dose ( RP2D ) combine afuresertib , independently 2 approve drug : enzalutamide ( Xtandi® , `` Xtandi trademark Astellas Pharma , Inc. '' ) abiraterone ( Zygita® , `` Zytiga trademark Janssen Biotech , Inc. '' ) . The study conduct two part . Part 1 , dose escalation phase , establish RP2D afuresertib administer enzalutamide abiraterone . Part 2 , dose expansion phase , evaluate long-term safety combination RP2Ds additional subject . Dose-finding cohort study parallel evaluate safety pharmacokinetic guide selection dose regimens evaluation . Part 2 begin RP2Ds establish Part 1 . Additional dos and/or schedule may explore warrant , base upon pharmacokinetic ( PK ) pharmacodynamic ( PD ) assessments emerge preclinical evidence . Overall , approximately 60 chemotherapy-naïve subject mCRPC receive either enzalutamide abiraterone enrol study .</brief_summary>
	<brief_title>Dose-Finding Study Afuresertib Administered Combination With Either Enzalutamide Aibraterone</brief_title>
	<detailed_description />
	<mesh_term>Prednisone</mesh_term>
	<criteria>Signed write informed consent provide Males &gt; =18 year age ( time consent obtain ) Histologically cytologically confirm diagnosis metastatic prostate adenocarcinoma , without neuroendocrine small cell feature Surgically medically castrate , testosterone level &lt; =50 nanogram ( ng ) /deciliter ( dL ) ( &lt; =1.73 nanomolar [ nM ] ) . If subject treat luteinizing hormone release hormone analog ( subject undergone orchiectomy ) , therapy must initiate least 4 week prior Cycle 1 Day 1 must continue throughout study . Rising Prostatespecific antigen ( PSA ) initial response enzalutamide abiraterone without radiographic symptomatic evidence progression ( per Prostate Cancer Working Group 2 criterion ) : Most recent enzalutamide dose receive 160 milligram ( mg ) daily change dose least 4 week prior Cycle 1 , Day 1 . Most recent abiraterone dose receive 1000 mg daily prednisone 5 mg twice daily ( BID ) , change dose least 2 week prior Cycle 1 , Day 1 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Able swallow retain orally administer medication . Adequate baseline organ function define : Absolute neutrophils count &gt; =1.5 x 10^9/Liter ( L ) , hemoglobin &gt; =9 gram ( g ) /dL , Platelets &gt; =75 x 10^9/L , Prothrombin time/International normalize ratio &lt; =1.3 x Upper limit normal ( ULN ) , Partial thromboplastin time &lt; =1.3 x ULN , Albumin &gt; =2.5 g/dL , Total bilirubin &lt; =1.5 ULN , Aspartate aminotranseferase Alanine aminotransferase &lt; =2.5 x ULN , Serum creatinine &lt; =ULN OR Estimated glomerular filtration rate &gt; =30 millilite per Minute ( mL/min ) , Fasting Serum Glucose &lt; 126 mg/dL , Hemoglobin A1C &lt; =8 % . Note : Subjects ALT bilirubin value outside range note table due Gilbert 's syndrome asymptomatic gallstone exclude . Male subject female partner childbearing potential must either prior vasectomy agree use effective contraception time first dose study treatment 3 month last dose study treatment . Prior treatment cytotoxic chemotherapy inhibitor Phosphoinositide 3kinase ( PI3K ) /protein kinase B ( AKT ) / mechanistic target rapamycin ( mTOR ) pathway . Any investigational drug ( ) within 30 day 5 halflives enrollment , whichever longer . Prior malignancy Castrateresistant prostate cancer ( CRPC ) . Exception : Subjects diseasefree prior malignancy 3 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . Any unresolved &gt; =Grade 2 ( per Common Toxicity Criteria Adverse Events 4.0 ) toxicity previous anticancer therapy time enrollment , except alopecia Grade 2 anemia ( hemoglobin &gt; 9.0 gram ( g ) /dL ) . Presence clinically significant gastrointestinal ( GI ) abnormality condition ( ) may alter absorption malabsorption syndrome major resection stomach substantial portion small intestine . NOTE : If clarification need whether GI abnormality , condition resection significantly affect absorption study treatment , contact Sponsor 's Medical Monitor . Major surgery , radiation therapy , immunotherapy within 28 day prior enrollment . Known active infection require intravenous ( IV ) oral antiinfective treatment . Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , hepatic , renal cardiac disease ) . For subject receive afuresertib plus enzalutamide : History seizure , underlie brain injury loss consciousness , transient ischemic attack past 12 month , cerebral vascular accident , brain metastasis , brain arteriovenous malformation , use concomitant medication may lower subject ' seizure threshold . History evidence cardiovascular risk include follow : Clinically significant ECG abnormality include second degree ( Type II ) third degree atrioventricular block . History myocardial infarction , acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting , bypass grafting within past 6 month prior enrollment . Class III IV heart failure define New York Heart Association functional classification system Left ventricular ejection fraction ( LVEF ) 50 % Known cardiac metastasis Corrected QT interval &gt; 470 millisecond ( msec ) ( &gt; 480 msec bundle branch block ) Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate afuresertib , enzalutamide , abiraterone , excipients . Any serious and/or unstable preexist medical , psychiatric disorder condition could interfere subject 's safety , obtain informed consent compliance study procedure . Have know Human Immunodeficiency Virus ( HIV ) infection . Subjects Hepatitis B surface antigen ( HbSAg ) positive . Subjects positive test Hepatitis C virus ( HCV ) antibody , regardless viral load . ( Note : subject eligible confirmatory recombinant immunoblot assay [ RIBA ] test negative ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Metastatic Castration-Resistant Prostate Cancer</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>Abiraterone</keyword>
	<keyword>Dose-Finding</keyword>
	<keyword>Afuresertib</keyword>
</DOC>